Market Newsdesk

NEW YORK, April 02, 2025 (GLOBE NEWSWIRE) — Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer of Syndax, as well as members of the Syndax management team, will participate in a fireside chat at the Stifel 2025 Virtual Targeted Oncology Forum on Wednesday, April 9, 2025, at 10:30 a.m. ET.

A live webcast of the fireside chat will be available in the Investor section of the Company’s website at www.syndax.com, where a replay will also be available for a limited time.

About Syndax

Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies. Highlights of the Company’s pipeline include Revuforj^® (revumenib), an FDA-approved menin inhibitor, and Niktimvo™ (axatilimab-csfr), an FDA-approved monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. Fueled by our commitment to reimagining cancer care, Syndax is working to unlock the full potential of its pipeline and is conducting several clinical trials across the continuum of treatment. For more information, please visit www.syndax.com or follow the Company on X and LinkedIn.

Syndax Contacts

Sharon Klahre
Syndax Pharmaceuticals, Inc.
[email protected]
Tel 781.684.9827

SNDX-G

• Initial draw at close of $50 million, with up to a total of $300 million available upon entry into definitive project loan documentation
• Early-stage investment from a division of Macquarie Group, one of the world’s largest infrastructure investors, further validates the attractiveness of Bitfarms’ potential HPC data center development pipeline, especially its near-term project at Panther Creek
• A $300 million facility is expected to provide the necessary capital for Bitfarms to fund the initial portion of the Panther Creek data center development and buildout in a non-dilutive manner

This news release constitutes a “designated news release” for the purposes of the Company’s amended and restated prospectus supplement dated December 17, 2024, to its short form base shelf prospectus dated November 10, 2023.

TORONTO, Ontario and BROSSARD, Québec, April 02, 2025 (GLOBE NEWSWIRE) — Bitfarms Ltd. (Nasdaq/TSX: BITF), a global energy and compute infrastructure company (“Bitfarms” or the “Company”), announced today that the Company has entered into an initial agreement for a private debt facility for up to $300 million from Macquarie Equipment Capital, Inc., a division of Macquarie Group’s Commodities and Global Markets’ business (“Macquarie”). The initial tranche of the facility is $50 million at the parent level and proceeds will be used for project development soft costs and other general corporate purposes. The second tranche of the facility may be up to $250 million and is drawable as the Company achieves specific development milestones at its Panther Creek location, at which time the entirety of the loan becomes secured at the project level only, resulting in a total project debt facility of $300 million and termination of the initial loan. The maturity of each facility is two years from the date of closing and each facility bears an interest at a rate of 8% per annum, with interest on the initial draw of $50 million paid in kind for the first three months. Draws under the second tranche of the facility are subject to the entry into definitive documentation, mutually agreed between the Company and Macquarie, on terms appended to the initial agreement, in addition to certain other conditions.

CEO Ben Gagnon stated, “We are thrilled to partner with Macquarie, a global leader in infrastructure investment with deep expertise and relationships across the HPC-related infrastructure value chain. This partnership marks the beginning of our investment in the near-term development of our Panther Creek data center, strategically located in Pennsylvania’s PJM region within close proximity to Philadelphia and NYC metropolitan areas. Panther Creek alone has a potential capacity of nearly 500 MW, supported by multiple power sources. Having multiple energy sources enhances reliability and redundancy while reducing anticipated CapEx and OpEx for HPC, making these sites particularly attractive to potential HPC customers. We are confident that this partnership will not only accelerate our buildout at Panther Creek, but also open doors to future opportunities with Macquarie as we look to scale our project and potentially expand to other sites within our portfolio.

“Amidst the surging AI revolution and the growing demand for power and infrastructure, this financing arrives at a pivotal time following the close of our transformational acquisition of Stronghold Digital Mining and the recent appointments of both James Bond, SVP of HPC, and Craig Hibbard, SVP of Infrastructure. We believe the analyses provided by our strategic partners, ASG and WWT, along with Macquarie’s due diligence and industry expertise, validate our HPC opportunity thesis at Panther Creek, strengthen our HPC pipeline and strategy, and position Bitfarms as a market leader in sourcing and developing large-scale, high-quality HPC data center projects.”

Joshua Stevens, Associate Director, Macquarie Group’s Commodities and Global Markets business, said, “We are proud to partner with Bitfarms and look forward to supporting the continued development of its innovative Panther Creek project, as well as future infrastructure that will be essential to the advancement of AI. Panther Creek is well located, within 100 miles of New York City and Philadelphia, and we expect it will be sought after by HPC tenants once construction of the project is underway.”

CFO Jeff Lucas stated, “Our highly valued North American assets, strong cash flow from mining operations, and the potential for higher-margin, stable, and predictable earnings characteristic of an HPC business model have enabled us to secure this attractive debt financing from a respected infrastructure partner. With an interest rate of 8%, we believe we can fund our energy and HPC infrastructure development at a significantly lower cost of capital and with much less dilution than equity funding, creating long-term shareholder value. The net proceeds from the initial $50 million will accelerate the launch of our HPC project at Panther Creek and finance the soft costs as we move forward with the HPC development. Importantly, this valuable partnership with Macquarie provides the necessary capital and expertise in datacenter development to accelerate our next chapter of growth.”

Key Financing Terms

• The $300 million project loan is intended to fund the development of the data center project at Panther Creek.
• The $50 million initial tranche of the facility, which is earmarked for project development soft costs and other general corporate purposes, is at the parent level and is secured by a first priority lien on all assets of the U.S. and Canadian guarantors and the borrower, with customary exclusions. The second tranche of the facility will be for up to $250 million and will be drawable as the Company achieves specific development milestones at its Panther Creek location and upon entering definitive documentation, at which time the entirety of the loan will become secured at the project level only and would result in a total project debt facility of $300 million and termination of the initial loan.
• The maturity of each facility is two years from the date of closing. Each facility will bear interest at a rate of 8% per annum, with interest on the initial draw of $50 million paid in kind for the first three months. 
• In connection with the initial tranche of the facility, Macquarie will receive warrants for the purchase of $5 million in shares of Bitfarms at a strike price equal to a 25% premium to the average of the past 5 days’ closing price (subject to a minimum strike price floor equal to the last closing price of Bitfarms’ shares on the TSX) and with a tenor of five years. The warrants and underlying shares are subject to customary registration rights for the resale of the underlying shares. Up until $125 million has been drawn under the second tranche of the facility, Macquarie will receive warrants equal to 10% of the amount drawn under the facility at a strike price equal to a 25% premium to the average of the past 5 days’ closing price (subject to a minimum strike price floor equal to the last closing price of Bitfarms’ shares on the TSX prior to grant) with a tenor of five years.
• The loan agreement for the initial tranche of the facility includes various affirmative and negative covenants for Bitfarms and its subsidiaries, including restrictions on dispositions, dividends, the incurrence of debt and liens, material changes in the nature of its business, related party transactions, and investments, in each case subject to certain customary exclusions and carveouts. In addition, Bitfarms must maintain a minimum of $25 million balance in cash at all times while the initial tranche is outstanding and must deposit additional amounts of cash if the average bitcoin price drops below certain thresholds as provided in the loan agreement (which funds will be returned if the bitcoin price returns to the previous thresholds).

Northland Capital Markets acted as sole placement agent to the Company. Skadden, Arps, Slate, Meagher & Flom LLP acted as legal counsel to the Company. Latham & Watkins LLP acted as legal counsel to Macquarie.

About Bitfarms Ltd.

Founded in 2017, Bitfarms is a global energy and compute infrastructure company that develops, owns, and operates vertically integrated HPC and Bitcoin mining data centers. Bitfarms currently has 15 operating Bitcoin data centers situated in four countries: the United States, Canada, Argentina and Paraguay.

Powered primarily by environmentally friendly hydro-electric and long-term power contracts, Bitfarms is committed to using sustainable and often underutilized energy infrastructure.

To learn more about Bitfarms’ events, developments, and online communities:

www.bitfarms.com.

https://www.facebook.com/bitfarms/

http://x.com/Bitfarms_io

https://www.instagram.com/bitfarms/

https://www.linkedin.com/company/bitfarms/

About
Macquarie
Group

Macquarie Group Limited (Macquarie) is a global financial services group providing clients with asset management, retail and business banking, wealth management, leasing and asset financing, market access, commodity trading, renewables development, specialist advice and access to capital and principal investment. Founded in 1969, Macquarie employs over 20,000 people in 34 markets. Commodities and Global Markets (CGM), an operating group of Macquarie, has more than 40 years of partnering with clients to provide capital and financing, risk management, market access, and physical execution and logistics solutions across commodities, financial markets, and asset finance sectors. For further information, visit www.macquarie.com.

Glossary of Terms

• MW = Megawatts or megawatt hour
• HPC/AI = High Performance Computing / Artificial Intelligence
• CapEx = Capital Expenditure
• OpEx = Operating Expenses
• PJM = Pennsylvania- New Jersey-Massachusetts regional transmission market
• NYC = New York City
• WWT = World Wide Technology
• ASG= Applebee Strategy Group, LLC

Forward-Looking Statements

This news release contains certain “forward-looking information” and “forward-looking statements” (collectively, “forward-looking information”) that are based on expectations, estimates and projections as at the date of this news release and are covered by safe harbors under Canadian and United States securities laws. The statements and information in this release regarding the completion of definitive documentation relating to the second tranche of the facility and the draw of an additional $250 million in funds, the development of the Company’s Panther Creek data center, its potential capacity, and its attractiveness to potential HPC customers, and other statements regarding future growth, plans and objectives of the Company are forward-looking information.

Any statements that involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “prospects”, “believes” or “intends” or variations of such words and phrases or stating that certain actions, events or results “may” or “could”, “would”, “might” or “will” be taken to occur or be achieved) are not statements of historical fact and may be forward-looking information.

This forward-looking information is based on assumptions and estimates of management of Bitfarms at the time they were made, and involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance, or achievements of Bitfarms to be materially different from any future results, performance or achievements expressed or implied by such forward-looking information. Such factors, risks and uncertainties include, among others: the ability to successfully negotiate and deliver definitive documentation relating to the second tranche of the facility, that the second tranche may not close within the timeframe anticipated or at all or may not close on the terms and conditions currently anticipated by the parties; the development and operation of Panther Creek may not occur as currently planned, or at all; expansion of existing facilities may not materialize as currently anticipated, or at all; new miners may not perform up to expectations; revenue may not increase as currently anticipated, or at all; the ongoing ability to successfully mine digital currency is not assured; failure of the equipment upgrades to be installed and operated as planned; the availability of additional power may not occur as currently planned, or at all; expansion may not materialize as currently anticipated, or at all; the power purchase agreements and economics thereof may not be as advantageous as expected; potential environmental cost and regulatory penalties due to the operation of plants which entail environmental risk and certain additional risk factors including, land reclamation requirements may be burdensome and expensive, changes in tax credits related to coal refuse power generation could have a material adverse effect on the business, financial condition, results of operations and future development efforts, competition in power markets may have a material adverse effect on the results of operations, cash flows and the market value of the assets, the business is subject to substantial energy regulation and may be adversely affected by legislative or regulatory changes, as well as liability under, or any future inability to comply with, existing or future energy regulations or requirements, the operations are subject to a number of risks arising out of the threat of climate change, and environmental laws, energy transitions policies and initiatives and regulations relating to emissions and coal residue management, which could result in increased operating and capital costs and reduce the extent of business activities, operation of power generation facilities involves significant risks and hazards customary to the power industry that could have a material adverse effect on our revenues and results of operations, and there may not have adequate insurance to cover these risks and hazards, employees, contractors, customers and the general public may be exposed to a risk of injury due to the nature of the operations, limited experience with carbon capture programs and initiatives and dependence on third-parties, including consultants, contractors and suppliers to develop and advance carbon capture programs and initiatives, and failure to properly manage these relationships, or the failure of these consultants, contractors and suppliers to perform as expected, could have a material adverse effect on the business, prospects or operations; the digital currency market; the ability to successfully mine digital currency; it may not be possible to profitably liquidate the current digital currency inventory, or at all; a decline in digital currency prices may have a significant negative impact on operations; an increase in network difficulty may have a significant negative impact on operations; the volatility of digital currency prices; the anticipated growth and sustainability of hydroelectricity for the purposes of cryptocurrency mining in the applicable jurisdictions; the inability to maintain reliable and economical sources of power to operate cryptocurrency mining assets; the risks of an increase in electricity costs, cost of natural gas, changes in currency exchange rates, energy curtailment or regulatory changes in the energy regimes in the jurisdictions in which Bitfarms operates and the potential adverse impact on profitability; future capital needs and the ability to complete current and future financings, including Bitfarms’ ability to utilize an at-the-market offering program ( “ATM Program”) and the prices at which securities may be sold in such ATM Program, as well as capital market conditions in general; share dilution resulting from an ATM Program and from other equity issuances; volatile securities markets impacting security pricing unrelated to operating performance; the risk that a material weakness in internal control over financial reporting could result in a misstatement of financial position that may lead to a material misstatement of the annual or interim consolidated financial statements if not prevented or detected on a timely basis; historical prices of digital currencies and the ability to mine digital currencies that will be consistent with historical prices; and the adoption or expansion of any regulation or law that will prevent Bitfarms from operating its business, or make it more costly to do so. For further information concerning these and other risks and uncertainties, refer to Bitfarms’ filings on

www.sedarplus.ca

(which are also available on the website of the U.S. Securities and Exchange Commission (the “
SEC
“) at
www.sec.gov
), including the Management’s Discussion & Analysis for the year-ended December 31, 2024. Although Bitfarms has attempted to identify important factors that could cause actual results to differ materially from those expressed in forward-looking statements, there may be other factors that cause results not to be as anticipated, estimated or intended, including factors that are currently unknown to or deemed immaterial by Bitfarms. There can be no assurance that such statements will prove to be accurate as actual results, and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on any forward-looking information. Bitfarms does not undertake any obligation to revise or update any forward-looking information other than as required by law. Trading in the securities of the Company should be considered highly speculative. No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein. Neither the Toronto Stock Exchange, Nasdaq, or any other securities exchange or regulatory authority accepts responsibility for the adequacy or accuracy of this release.

Investor Relations Contact:

Tracy Krumme
SVP, Head of IR & Corp. Comms.
+1 786-671-5638
[email protected]

Media Contact:

Caroline Brady Baker
Director, Communications
[email protected]

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/bab8a34f-c6c6-4802-bf43-e7edcb378236

– Preclinical presentation highlights key, modality specific, pharmacological differentiations of VG-3927 – 

– First presentation of topline clinical data from Phase 1 SAD/MAD trial of VG-3927 for the potential treatment of Alzheimer’s disease (AD) –

WATERTOWN, Mass., April 02, 2025 (GLOBE NEWSWIRE) — Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today presented data highlighting its oral small molecule program, including its lead clinical candidate VG-3927, in two oral presentations at the AD/PD™ 2025 International Conference on Alzheimer’s and Parkinson’s Diseases being held April 1 – April 5 in Vienna, Austria.

“We are thrilled to showcase our preclinical and Phase 1 data on VG-3927 at AD/PD™,” said Ivana Magovčević-Liebisch, Ph.D., J.D., President and Chief Executive Officer of Vigil. “Today’s two presentations highlight the unique potential of VG-3927 as an orally bioavailable, highly potent and CNS penetrant small molecule TREM2 agonist and provide the complete dataset from the positive Phase 1 results that we announced earlier this year. Collectively, VG-3927’s favorable safety, tolerability, PK and PD profile support the advancement of this program as a differentiated next-generation therapeutic candidate that may go beyond what is possible with amyloid-based therapies to also target other, unaddressed contributors of disease progression in AD. We are looking forward to progressing VG-3927 as the first and only oral, once-daily, clinical-stage small molecule TREM2 agonist into Phase 2 development in the third quarter of this year.”

Oral presentation by Christian Mirescu, Ph.D., Senior Vice President, Neuroimmunology: Small Molecule TREM2 Agonists as Next-Generation Therapeutics for Alzheimer’s Disease 


Date and Time: Wednesday, April 2, 2025, 3:20 PM – 3:35 PM (CET) 
Session: TREM2, Microglia: From Mechanisms to Potential Treatments

Key highlights from this presentation demonstrated:

• VG-3927 is an orally bioavailable small molecule TREM2 agonist that has high specificity for membrane-bound TREM2 versus soluble TREM2 (sTREM2), which leads to increased access to the therapeutic site of action.
• VG-3927 shows a unique, synergistic activation of TREM2 with endogenous TREM2 ligands such as aggregated amyloid-beta (Aβ) that is expected to drive enhanced potency and specificity in regions of pathology.
• New data in 5xFAD plaque-burdened mice illustrate that small molecule TREM2 agonism enhances microglial uptake of both Aβ and Tau supporting the broad efficacy potential of the TREM2 agonist approach to go beyond targeting a single driver of AD pathology.

“In addition to the existing evidence supporting TREM2 as a therapeutic target in AD, our continued interrogation of VG-3927 has demonstrated that by activating TREM2, we can engage the brain’s immune system to counter multiple pathologies,” said Christian Mirescu, Ph.D., Senior Vice President, Neuroimmunology of Vigil. “By promoting microglial uptake of both Aβ and Tau, this program has the potential to be a transformative treatment option in AD as a once-daily oral therapy.”

Oral presentation by Petra Kaufmann, M.D., F.A.A.N., Chief Medical Officer: Phase 1 Study of VG-3927, A Novel Oral TREM2 Agonist 


Date and Time: Wednesday, April 2, 2025, 3:35 PM – 3:50 PM (CET) 
Session: TREM2, Microglia: From Mechanisms to Potential Treatments

Key highlights from the presentation:

• The Phase 1 trial of 115 participants provided a comprehensive and robust dataset evaluating healthy volunteers, elderly participants and a cohort of AD patients.
• VG-3927 demonstrated a favorable safety and tolerability profile across all cohorts with no serious adverse events.
• All treatment-related adverse events (AEs) were mild or moderate and self-resolving.
• VG-3927 showed a predictable and dose-dependent pharmacokinetic (PK) profile that supports once-daily dosing. These data demonstrated that VG-3927 has high CNS penetrance with an estimated cerebral spinal fluid (CSF) to unbound plasma ratio of 0.91.
• PK and sTREM2 reduction observed in the single dose AD cohort was consistent with healthy volunteers and the reduction in sTREM2 was similar across evaluated TREM2 and ApoE genetic variants supporting development in AD across genotypes.
• PK and sTREM2 reduction observed in the multiple ascending dose (MAD) elderly cohort was consistent with healthy volunteers.
• At the 25 mg dose, VG-3927 achieved the maximum sTREM2 reduction in the CSF of approximately 50%.
• PK/PD data support the selection of a 25 mg once-daily oral dose for the Phase 2 trial in AD patients.

“Our extensive preclinical and Phase 1 data give us confidence that VG-3927 is a highly CNS penetrant molecule that effectively engages TREM2, harnessing the neuroprotective capabilities of microglia,” said Petra Kaufmann, M.D., F.A.A.N., Chief Medical Officer of Vigil. “By targeting TREM2, we believe VG-3927 can reduce neuroinflammation and promote microglial health to address the underlying AD pathology. We are committed to advancing this program with the goal of providing a new and differentiated therapeutic option for individuals affected by AD that may improve the treatment paradigm and patient outcomes.”

About the Phase 1 Trial

The Phase 1 single and multiple ascending dose (SAD/MAD) trial assessed the safety, tolerability, PK, and PD of VG-3927 across 14 cohorts. As part of this trial, the Company evaluated 8 SAD cohorts of healthy volunteers up to a 140 mg dose and 4 MAD cohorts of healthy volunteers up to a 50 mg dose. The trial also included an elderly cohort and a single dose cohort of 11 AD patients, including some participants who carry TREM2 or other genetic risk factors for AD. The trial enrolled a total of 115 participants. Eighty-nine (89) participants received VG-3927, including 34 who were 55 years of age and older.

About VG-3927

VG-3927 is a potent orally bioavailable small molecule TREM2 agonist. Its novel mode of action as both an agonist and a positive allosteric modulator (PAM) may amplify functional responses around sites of pathology leading to strong modulation of microglia and potentially greater neuroprotection. VG-3927 is designed to enhance protective microglial responses to aggregated amyloid and tau without increasing inflammation. In contrast to antibody TREM2 agonists, VG-3927 maximizes receptor activation and microglial function because it does not bind to sTREM2, which may increase its access to the site of therapeutic action in AD. Additionally, VG-3927 does not have an Fc (fragmented crystallizable region) domain, which engages elements of the immune system that have been associated with increased risk of amyloid-related imaging abnormalities (ARIA). Collectively across preclinical and clinical data, these key differentiators create a compelling profile for VG-3927 as an investigational next-generation therapy for the treatment of AD.

About Vigil Neuroscience

Vigil Neuroscience is a clinical-stage biotechnology company focused on developing treatments for both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Vigil is utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities in its efforts to develop precision-based therapies to improve the lives of patients and their families. Iluzanebart, Vigil’s lead clinical candidate, is a fully human monoclonal antibody agonist targeting triggering receptor expressed on myeloid cells 2 (TREM2) in people with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease. Vigil is also developing VG-3927, a novel small molecule TREM2 agonist, to treat common neurodegenerative diseases associated with microglial dysfunction, with an initial focus on Alzheimer’s disease (AD).

Forward-Looking Statements

This press release includes certain disclosures that contain “forward-looking statements” of Vigil Neuroscience (“Vigil” or the “Company”) that are made pursuant to the safe harbor provisions of the federal securities laws, including, without limitation, express or implied statements regarding: the Company’s strategy, business plans and focus; the potential therapeutic benefit of the Company’s product candidates, including VG-3927; the progress and timing of the clinical development of Vigil’s programs, including the expected progress and timing to advance VG-3927 into a Phase 2 clinical trial in the third quarter of 2025; and beliefs about observations made analyzing preclinical study and clinical trial data to date, including with respect to VG-3927. Forward-looking statements are based on Vigil’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, risks and uncertainties inherent in the development of product candidates, including the conduct of research activities and clinical trials; whether results from prior preclinical studies and clinical trials will be predictive of the results of subsequent preclinical studies and clinical trials; and the timing and content of additional regulatory information from the FDA; as well as the risks and uncertainties identified in the Company’s filings with the Securities and Exchange Commission (SEC), including Vigil’s Annual Report on Form 10-K for the year ended December 31, 2024 and any subsequent filings Vigil makes with the SEC. Forward-looking statements contained in this announcement are made as of this date, and Vigil undertakes no duty to update such information except as required under applicable law. Readers should not rely upon the information on this page as current or accurate after its publication date.

Internet Posting of Information

Vigil Neuroscience routinely posts information that may be important to investors in the “Investors” section of its website at https://www.vigilneuro.com. The company encourages investors and potential investors to consult our website regularly for important information about Vigil Neuroscience.

Investor Contact:

Leah Gibson
Vice President, Investor Relations & Corporate Communications
Vigil Neuroscience, Inc.
[email protected] 

Media Contact:

Megan McGrath
CTD Comms, LLC
[email protected] 

LONDON, April 02, 2025 (GLOBE NEWSWIRE) — Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, announces that the Company will participate in the 24^th Annual Needham Virtual Healthcare Conference.

Autolus Chief Executive Officer Dr. Christian Itin will present in a Fireside Chat on Wednesday, April 9, 2025 at 9:30am EDT / 14:30pm BST.

A webcast of the fireside chat will be available on the “Events” page in the “Investor Relations & Media” section of the Company’s website at https://www.autolus.com/investor-relations-media/events/. A replay of the webcast will be archived on the Company’s website for 90 days following the presentation.

About Autolus Therapeutics plc

Autolus Therapeutics plc (Nasdaq: AUTL) is an early commercial stage biopharmaceutical company developing, manufacturing and delivering next-generation T cell therapies for the treatment of cancer and autoimmune disease. Using a broad suite of proprietary and modular T cell programming technologies, Autolus is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize target cells, break down their defense mechanisms and eliminate these cells. Autolus has an FDA approved product, AUCATZYL, and a pipeline of product candidates in development for the treatment of hematological malignancies, solid tumors and autoimmune diseases. For more information, please visit www.autolus.com

Contact:

Amanda Cray 
+1 617-967-0207 
[email protected] 

Olivia Manser 
+44 7780 471 568 
[email protected] 

MIAMI, April 02, 2025 (GLOBE NEWSWIRE) — Norwegian Cruise Line Holdings Ltd. (NYSE: NCLH) (the “Company”) and NCL Corporation Ltd., a subsidiary of the Company (“NCLC”), announce that NCLC has entered into individually negotiated note exchange agreements with certain existing holders (the “Holders”) of NCLC’s 5.375% Exchangeable Senior Notes due 2025 (the “2025 Notes”), pursuant to which NCLC and the Holders have agreed to exchange (the “Exchange”) $285,425,000 in aggregate principal amount of the Holders’ 2025 Notes for (i) $285,425,000 in aggregate principal amount of NCLC’s newly issued 0.875% Exchangeable Senior Notes due 2030 (the “2030 Notes”) and (ii) an aggregate cash payment (the “Cash Payment”) of $51,624,820, plus accrued and unpaid interest on the 2025 Notes to be exchanged to, but excluding, the closing date of the Exchange. The Cash Payment will be equal to the proceeds from the concurrent Equity Offering, as described below, and represents the remainder of NCLC’s exchange obligation in excess of the aggregate principal amount of the 2025 Notes to be exchanged.

Concurrently, the Company announces a registered direct offering of 2,708,533 ordinary shares to the Holders at a price of $19.06 per share (the “Equity Offering” and together with the Exchange, the “Transactions”). The Company expects to use the proceeds from the Equity Offering to make the Cash Payment.

The closing of the Transactions is expected to occur on or about April 7, 2025, subject to customary closing conditions. Following the Exchange, approximately $164,565,000 in aggregate principal amount of the 2025 Notes will remain outstanding. The Transactions will be neutral to the Company’s leverage and, as of closing of the Transactions, are expected to reduce the Company’s shares outstanding on a fully diluted basis by approximately 12.5 million shares.

The 2030 Notes will be general senior unsecured obligations of NCLC and guaranteed by the Company. Holders may exchange all or a portion of the 2030 Notes at the holder’s option (i) at any time prior to the close of business on the business day immediately preceding October 15, 2029, subject to the satisfaction of certain conditions and during certain periods, and (ii) on or after October 15, 2029 until the close of business on the business day immediately preceding the maturity date, regardless of whether such conditions have been met. Upon exchange of the 2030 Notes, NCLC will satisfy its exchange obligation by paying cash up to the aggregate principal amount of the 2030 Notes to be exchanged and paying or delivering, as the case may be, cash, ordinary shares or a combination of cash and ordinary shares, at NCLC’s election, in respect of the remainder, if any, of NCLC’s exchange obligation in excess of the aggregate principal amount of the 2030 Notes to be exchanged. The initial exchange rate per $1,000 principal amount of 2030 Notes is 38.1570 ordinary shares, which is equivalent to an initial exchange price of approximately $26.21 per ordinary share, subject to adjustment in certain circumstances. The initial exchange price represents a premium of approximately 37.5% above the offering price in the Equity Offering.

Barclays Capital Inc. is acting as the exclusive placement agent for the Equity Offering. The Equity Offering is being made under an automatic shelf registration statement filed with the U.S. Securities and Exchange Commission (“SEC”) on November 8, 2023. The Equity Offering may be made only by means of a prospectus supplement and the accompanying prospectus, which will be filed with the SEC and will be available on the SEC’s website at www.sec.gov.

The 2030 Notes are being issued in a private placement in reliance on the exemption from registration provided by Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”). The 2030 Notes, the guarantee of the Company and the ordinary shares issuable upon the exchange of the 2030 Notes, if any, will not be registered under the Securities Act or the securities laws of any other jurisdiction and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the Securities Act and applicable state laws.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy any security and shall not constitute an offer, solicitation or sale in any jurisdiction in which such an offer, solicitation or sale would be unlawful prior to the registration and qualification under the securities laws of such state or jurisdiction.

About Norwegian Cruise Line Holdings Ltd.

Norwegian Cruise Line Holdings Ltd. (NYSE: NCLH) is a leading global cruise company that operates Norwegian Cruise Line, Oceania Cruises and Regent Seven Seas Cruises. With a combined fleet of 33 ships and approximately 70,050 berths, NCLH offers itineraries to approximately 700 destinations worldwide. NCLH expects to add 12 additional ships across its three brands through 2036, which will add approximately 37,500 berths to its fleet.

Cautionary Statement Concerning Forward-Looking Statements

Some of the statements, estimates or projections contained in this press release are “forward-looking statements” within the meaning of the U.S. federal securities laws intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this press release, including statements regarding the Transactions, may be forward-looking statements. Many, but not all, of these statements can be found by looking for words like “expect,” “anticipate,” “goal,” “project,” “plan,” “believe,” “seek,” “will,” “may,” “forecast,” “estimate,” “intend,” “future” and similar words. Forward-looking statements do not guarantee future performance and may involve risks, uncertainties and other factors which could cause our actual results, performance or achievements to differ materially from the future results, performance or achievements expressed or implied in those forward-looking statements. For a discussion of these risks, uncertainties and other factors, please refer to the factors set forth under the sections entitled “Risk Factors” and “Cautionary Statement Concerning Forward-Looking Statements” in our most recently filed Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and subsequent filings with the SEC. These factors are not exhaustive and new risks emerge from time to time. There may be additional risks that we consider immaterial or which are unknown. Such forward-looking statements are based on our current beliefs, assumptions, expectations, estimates and projections regarding our present and future business strategies and the environment in which we expect to operate in the future. These forward-looking statements speak only as of the date made. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statement to reflect any change in our expectations with regard thereto or any change of events, conditions or circumstances on which any such statement was based, except as required by law.

Investor Relations & Media Contact

Sarah Inmon
(786) 812-3233
[email protected]

– Onboarded over 10,000 accounts; averaging 1,000 new accounts per day with first digital banking partner –

– Second digital bank has completed API integrations and expects to begin onboarding mid-April –

SAN DIEGO, CA, April 02, 2025 (GLOBE NEWSWIRE) — RYVYL Inc. (NASDAQ: RVYL) (“RYVYL” or the “Company”), a leading innovator of payment transaction solutions leveraging electronic payment technology for the diverse international markets, is rapidly onboarding new accounts with its two recently announced digital banking partners at RYVYL EU – Mar. 20, 2025 – RYVYL Secures Major Payments-as-a-Service Contracts.

Under the first contract, a fast-growing financial services provider is leveraging RYVYL EU’s infrastructure to issue digital and physical payment accounts. So far:

• Over 10,000 accounts have been successfully opened;
• Onboarding is currently averaging 1,000 new accounts per day; and
• More than €10 million in transaction volume has been processed.
  

This contract is on track to exceed 50,000+ active accounts in 2025.

The second contract, with a fully digital banking platform, has completed API integrations ahead of plan and is scheduled to onboard 900,000 new customer accounts within the next 12 months.

Rui Helder, Chief Business Development Officer, RYVYL EU, said: “Our PaaS platform and support team offer partners exceptional value and means to leverage their customer base as well as accelerate growth. We are providing seamless onboarding, compliance expertise, and the operational scale required to power modern digital Payment ecosystems. Now, we are exceeding our initial onboarding goals for our two new PaaS contracts and are rapidly scaling our footprint with new accounts throughout Europe. I’m proud of our team’s strong execution in the initial onboarding of these key digital banking partners and confident we will reach our goal of opening nearly 1 million new customer accounts within the next 12 months.”

The foregoing guidance is based on the Company’s continuation of the business, as currently conducted. On January 24, 2025, the Company entered into an agreement with a financing source that was structured as a pre-funded asset sale with a 90-day closing period, which ends on April 23, 2025 and may be extended an additional 30 days to May 23, 2025, if the Company pays $500,000 for such extension. Shares in the Company’s RYVYL EU subsidiary were placed in escrow during the closing period. Although there are no guarantees, the Company intends to terminate the asset sale within the closing period by paying $16.5 million in consideration of such termination. The Company’s financial guidance for 2025 is based on fully retaining its RYVYL EU subsidiary.

About RYVYL

RYVYL Inc. (NASDAQ: RVYL) was born from a passion for empowering a new way to conduct business-to-business, consumer-to-business, and peer-to-peer payment transactions around the globe. By leveraging electronic payment technology for diverse international markets, RYVYL is a leading innovator of payment transaction solutions reinventing the future of financial transactions. Since its founding as GreenBox POS in 2017 in San Diego, RYVYL has developed applications enabling an end-to-end suite of turnkey financial products with enhanced security and data privacy, world-class identity theft protection, and rapid speed to settlement. As a result, the platform can log immense volumes of immutable transactional records at the speed of the internet for first-tier partners, merchants, and consumers around the globe. www.ryvyl.com

Cautionary Note Regarding Forward-Looking Statements

This press release includes information that constitutes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements are based on the Company’s current beliefs, assumptions, and expectations regarding future events, which in turn are based on information currently available to the Company. Such forward-looking statements include statements regarding the anticipated number of account activations and new customers onboarded, anticipated revenues and margins, timely payment of the second tranche, the benefit to stockholders from the repayment of the Note and repurchase of the Preferred Stock, and the timing and expectation of revenues from the contracts described herein and are charactered by future or conditional words such as “may,” “will,” “expect,” “intend,” “anticipate,” “believe,” “estimate” and “continue” or similar words. You should read statements that contain these words carefully because they discuss future expectations and plans, which contain projections of future results of operations or financial condition or state other forward-looking information. By their nature, forward-looking statements address matters that are subject to risks and uncertainties. A variety of factors could cause actual events and results to differ materially from those expressed in or contemplated by the forward-looking statements, including the risk that the licensee understands and complies with various banking laws and regulations that may impact the licensee’s ability to process transactions. For example, federal money laundering statutes and Bank Secrecy Act regulations discourage financial institutions from working with operators of certain industries – particularly industries with heightened cash reporting obligations and restrictions – as a result of which, banks may refuse to process certain payments and/or require onerous reporting obligations by payment processors to avoid compliance risk. These statements are also subject to any damages the Company could suffer as the result of previously announced litigation or actions of any governmental agencies. These and other risk factors affecting the Company are discussed in detail in the Company’s periodic filings with the SEC. The Company undertakes no obligation to publicly update or revise any forward-looking statement, whether because of the latest information, future events or otherwise, except to the extent required by applicable laws.

IR Contact:

David Barnard, Alliance Advisors Investor Relations, 415-433-3777, [email protected]

IRVINE, Calif., April 02, 2025 (GLOBE NEWSWIRE) — Lantronix Inc. (NASDAQ: LTRX), a global leader of compute and connectivity for IoT solutions enabling Edge AI Intelligence, today announced it has been recognized on the 2025 Internet of Things (IoT) 50 list by CRN^®, a brand of The Channel Company. CRN’s annual IoT 50 list spotlights vendors leading IoT innovation that are driving channel success. Honorees are selected by a panel of CRN editors with input from members of the channel partner community.

“We are very honored to be on CRN’s IoT 50 List that spotlights companies that are notable for their dedication to cutting-edge solutions that empower the channel to create and deliver groundbreaking IoT solutions,” said Saleel Awsare, president & CEO of Lantronix Inc. “This award is especially valued by our team as we are devoted to helping our channel partners deliver powerful Edge intelligent solutions for our mutual customers.”

Recognition on the list is based on the quality of the vendors’ IoT portfolios and consistency in delivering new opportunities for partners. Each company on the CRN IoT 50 has taken steps toward empowering its channel partners to deliver cutting-edge IoT solutions and drive growth. The CRN IoT 50 list includes five IoT categories: Hardware, Security, Software, Industrial and Networking and Connectivity. Lantronix was recognized in the Hardware category.  

“IoT solutions deliver critical data for better decision-making and are powerful growth drivers for the channel,” said Jennifer Follett, VP, U.S. Content, and Executive Editor, CRN, The Channel Company. “We’re pleased to spotlight these vendors for their dedication to empowering partners with IoT innovation that helps them better serve their clients and advance the entire IT channel.” 

The 2025 CRN IoT 50 list is featured in the April issue of CRN Magazine and online at www.CRN.com/IoT50. 

About The Channel Company

The Channel Company (TCC) is the global leader in channel growth for the world’s top technology brands. We accelerate success across strategic channels for tech vendors, solution providers, and end users with premier media brands, integrated marketing and event services, strategic consulting, and exclusive market and audience insights. TCC is a portfolio company of investment funds managed by EagleTree Capital, a New York City-based private equity firm. For more information, visit thechannelco.com.

About Lantronix

Lantronix Inc. is a global leader of compute and connectivity IoT solutions that target high-growth markets, including Smart Cities, Enterprise and Transportation. Lantronix’s products and services empower companies to succeed in the growing IoT markets by delivering customizable solutions that enable AI Edge Intelligence. Lantronix’s advanced solutions include Intelligent Substations infrastructure, Infotainment systems and Video Surveillance, supplemented with advanced Out-of-Band Management (OOB) for Cloud and Edge Computing.

For more information, visit the Lantronix website.

©2025 Lantronix, Inc. All rights reserved. Lantronix is a registered trademark. Other trademarks and trade names are those of their respective owners.

Lantronix Media Contact:        
Gail Kathryn Miller
Corporate Marketing &
Communications Manager
[email protected]

Lantronix Analyst and Investor Contact:        
[email protected]